The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors
Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase b...
Gespeichert in:
Veröffentlicht in: | The Journal of pharmacology and experimental therapeutics 2010-11, Vol.335 (2), p.434-442 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 442 |
---|---|
container_issue | 2 |
container_start_page | 434 |
container_title | The Journal of pharmacology and experimental therapeutics |
container_volume | 335 |
creator | Antonioli, Luca Fornai, Matteo Colucci, Rocchina Awwad, Oriana Ghisu, Narcisa Tuccori, Marco Da Settimo, Federico La Motta, Concettina Natale, Gianfranco Duranti, Emiliano Virdis, Agostino Blandizzi, Corrado |
description | Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation. |
doi_str_mv | 10.1124/jpet.110.171223 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_759521994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>759521994</sourcerecordid><originalsourceid>FETCH-LOGICAL-p125t-af6b1a60f1d8c4289b1c2527802f4c811eca22efa5ff17cc4a2f8118d84e00d3</originalsourceid><addsrcrecordid>eNpVkDtPwzAUhS0kREthZkPemAK247zGqIKCVImle3TjXFOXJA62I8Ef4HfjijIwnfv4dKRzCLnh7J5zIR8OE4Y4xa3gQqRnZMkzwRPGWbogl94fGONS5ukFWQiW5yXL0iX53u2Rtr1V79AhtZpGGa03I9IOYTAjeKQwYG-sg4Ceqr2zo1EUPyd0ZsAxQE-V7U0wnob4nN_2UZE6VG424Uj8961FTWHsaJ0eGZyCdf6KnGvoPV6fdEV2T4-79XOyfd28rOttMnGRhQR03nLImeZdqaQoq5YrkYmiZEJLVXKOCoRADZnWvFBKgtDxWnalRMa6dEXufm0nZz9m9KEZjFfY9zCinX1TZFWsrKpkJG9P5NwO2DVTzAruq_lrLv0BoQxxQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>759521994</pqid></control><display><type>article</type><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</creator><creatorcontrib>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</creatorcontrib><description>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</description><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.110.171223</identifier><identifier>PMID: 20668053</identifier><language>eng</language><publisher>United States</publisher><subject>Adenine - analogs & derivatives ; Adenine - pharmacology ; Adenine - therapeutic use ; Adenosine Deaminase - biosynthesis ; Adenosine Deaminase Inhibitors ; Animals ; Blotting, Western ; Body Weight - drug effects ; Chronic Disease ; Colitis - enzymology ; Colitis - immunology ; Colitis - metabolism ; Colitis - prevention & control ; Colon - drug effects ; Colon - enzymology ; Colon - immunology ; Colon - metabolism ; Cytokines - immunology ; Disease Models, Animal ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Male ; Organ Size - drug effects ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Rats ; Rats, Sprague-Dawley ; Receptor, Adenosine A2A - metabolism ; Receptor, Adenosine A3 - metabolism</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2010-11, Vol.335 (2), p.434-442</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20668053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Fornai, Matteo</creatorcontrib><creatorcontrib>Colucci, Rocchina</creatorcontrib><creatorcontrib>Awwad, Oriana</creatorcontrib><creatorcontrib>Ghisu, Narcisa</creatorcontrib><creatorcontrib>Tuccori, Marco</creatorcontrib><creatorcontrib>Da Settimo, Federico</creatorcontrib><creatorcontrib>La Motta, Concettina</creatorcontrib><creatorcontrib>Natale, Gianfranco</creatorcontrib><creatorcontrib>Duranti, Emiliano</creatorcontrib><creatorcontrib>Virdis, Agostino</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - pharmacology</subject><subject>Adenine - therapeutic use</subject><subject>Adenosine Deaminase - biosynthesis</subject><subject>Adenosine Deaminase Inhibitors</subject><subject>Animals</subject><subject>Blotting, Western</subject><subject>Body Weight - drug effects</subject><subject>Chronic Disease</subject><subject>Colitis - enzymology</subject><subject>Colitis - immunology</subject><subject>Colitis - metabolism</subject><subject>Colitis - prevention & control</subject><subject>Colon - drug effects</subject><subject>Colon - enzymology</subject><subject>Colon - immunology</subject><subject>Colon - metabolism</subject><subject>Cytokines - immunology</subject><subject>Disease Models, Animal</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Organ Size - drug effects</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptor, Adenosine A2A - metabolism</subject><subject>Receptor, Adenosine A3 - metabolism</subject><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkDtPwzAUhS0kREthZkPemAK247zGqIKCVImle3TjXFOXJA62I8Ef4HfjijIwnfv4dKRzCLnh7J5zIR8OE4Y4xa3gQqRnZMkzwRPGWbogl94fGONS5ukFWQiW5yXL0iX53u2Rtr1V79AhtZpGGa03I9IOYTAjeKQwYG-sg4Ceqr2zo1EUPyd0ZsAxQE-V7U0wnob4nN_2UZE6VG424Uj8961FTWHsaJ0eGZyCdf6KnGvoPV6fdEV2T4-79XOyfd28rOttMnGRhQR03nLImeZdqaQoq5YrkYmiZEJLVXKOCoRADZnWvFBKgtDxWnalRMa6dEXufm0nZz9m9KEZjFfY9zCinX1TZFWsrKpkJG9P5NwO2DVTzAruq_lrLv0BoQxxQA</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Antonioli, Luca</creator><creator>Fornai, Matteo</creator><creator>Colucci, Rocchina</creator><creator>Awwad, Oriana</creator><creator>Ghisu, Narcisa</creator><creator>Tuccori, Marco</creator><creator>Da Settimo, Federico</creator><creator>La Motta, Concettina</creator><creator>Natale, Gianfranco</creator><creator>Duranti, Emiliano</creator><creator>Virdis, Agostino</creator><creator>Blandizzi, Corrado</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><author>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p125t-af6b1a60f1d8c4289b1c2527802f4c811eca22efa5ff17cc4a2f8118d84e00d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - pharmacology</topic><topic>Adenine - therapeutic use</topic><topic>Adenosine Deaminase - biosynthesis</topic><topic>Adenosine Deaminase Inhibitors</topic><topic>Animals</topic><topic>Blotting, Western</topic><topic>Body Weight - drug effects</topic><topic>Chronic Disease</topic><topic>Colitis - enzymology</topic><topic>Colitis - immunology</topic><topic>Colitis - metabolism</topic><topic>Colitis - prevention & control</topic><topic>Colon - drug effects</topic><topic>Colon - enzymology</topic><topic>Colon - immunology</topic><topic>Colon - metabolism</topic><topic>Cytokines - immunology</topic><topic>Disease Models, Animal</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Organ Size - drug effects</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptor, Adenosine A2A - metabolism</topic><topic>Receptor, Adenosine A3 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Fornai, Matteo</creatorcontrib><creatorcontrib>Colucci, Rocchina</creatorcontrib><creatorcontrib>Awwad, Oriana</creatorcontrib><creatorcontrib>Ghisu, Narcisa</creatorcontrib><creatorcontrib>Tuccori, Marco</creatorcontrib><creatorcontrib>Da Settimo, Federico</creatorcontrib><creatorcontrib>La Motta, Concettina</creatorcontrib><creatorcontrib>Natale, Gianfranco</creatorcontrib><creatorcontrib>Duranti, Emiliano</creatorcontrib><creatorcontrib>Virdis, Agostino</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antonioli, Luca</au><au>Fornai, Matteo</au><au>Colucci, Rocchina</au><au>Awwad, Oriana</au><au>Ghisu, Narcisa</au><au>Tuccori, Marco</au><au>Da Settimo, Federico</au><au>La Motta, Concettina</au><au>Natale, Gianfranco</au><au>Duranti, Emiliano</au><au>Virdis, Agostino</au><au>Blandizzi, Corrado</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2010-11</date><risdate>2010</risdate><volume>335</volume><issue>2</issue><spage>434</spage><epage>442</epage><pages>434-442</pages><eissn>1521-0103</eissn><abstract>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</abstract><cop>United States</cop><pmid>20668053</pmid><doi>10.1124/jpet.110.171223</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1521-0103 |
ispartof | The Journal of pharmacology and experimental therapeutics, 2010-11, Vol.335 (2), p.434-442 |
issn | 1521-0103 |
language | eng |
recordid | cdi_proquest_miscellaneous_759521994 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adenine - analogs & derivatives Adenine - pharmacology Adenine - therapeutic use Adenosine Deaminase - biosynthesis Adenosine Deaminase Inhibitors Animals Blotting, Western Body Weight - drug effects Chronic Disease Colitis - enzymology Colitis - immunology Colitis - metabolism Colitis - prevention & control Colon - drug effects Colon - enzymology Colon - immunology Colon - metabolism Cytokines - immunology Disease Models, Animal Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Male Organ Size - drug effects Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyrimidines - pharmacology Pyrimidines - therapeutic use Rats Rats, Sprague-Dawley Receptor, Adenosine A2A - metabolism Receptor, Adenosine A3 - metabolism |
title | The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20blockade%20of%20adenosine%20deaminase%20ameliorates%20chronic%20experimental%20colitis%20through%20the%20recruitment%20of%20adenosine%20A2A%20and%20A3%20receptors&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Antonioli,%20Luca&rft.date=2010-11&rft.volume=335&rft.issue=2&rft.spage=434&rft.epage=442&rft.pages=434-442&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.110.171223&rft_dat=%3Cproquest_pubme%3E759521994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=759521994&rft_id=info:pmid/20668053&rfr_iscdi=true |